Vectibix Interactions
There are 31 drugs known to interact with Vectibix (panitumumab), along with 5 disease interactions. Of the total drug interactions, 12 are major, and 19 are moderate.
- View all 31 medications that may interact with Vectibix
- View Vectibix disease interactions (5)
Most frequently checked interactions
View interaction reports for Vectibix (panitumumab) and the medicines listed below.
- Adriamycin (doxorubicin)
- Aranesp (darbepoetin alfa)
- Avastin (bevacizumab)
- Blincyto (blinatumomab)
- Caprelsa (vandetanib)
- carboplatin
- Cipro (ciprofloxacin)
- Compazine (prochlorperazine)
- Complera (emtricitabine / rilpivirine / tenofovir disoproxil)
- Cosentyx (secukinumab)
- Cytoxan (cyclophosphamide)
- Decadron (dexamethasone)
- Detrol LA (tolterodine)
- dexamethasone
- Erivedge (vismodegib)
- Esbriet (pirfenidone)
- Fentanyl Transdermal System (fentanyl)
- fluorouracil
- Herceptin (trastuzumab)
- Idelvion (coagulation factor ix)
- irinotecan
- Kerendia (finerenone)
- leucovorin
- Lipitor (atorvastatin)
- Lomotil (atropine / diphenoxylate)
- losartan
- Luxturna (voretigene neparvovec ophthalmic)
- oxaliplatin
- Xgeva (denosumab)
- Zofran (ondansetron)
Vectibix disease interactions
There are 5 disease interactions with Vectibix (panitumumab) which include:
- CV/electrolyte imbalance
- dermatologic toxicities
- ocular disorders
- pulmonary toxicity
- liver/renal impairment
Report options
QR code containing a link to this page
More about Vectibix (panitumumab)
- Vectibix consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: EGFR inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.